Lonza released its Q1 16 trading statement, which, as usual, does not include hard numbers. The business development in Q1 is said to be good in both the Speciality Indredients and Pharma & Biotech segments. On this basis, the group expects a double-digit core EBIT growth in H1, while the full-year guidance will be discussed with the H1 results on 20 July. Note, so far, the FY16 guidance (released in January with the FY15 results) points to a growth in sales and a core EBIT growth of at l
26 Apr 2016
Q1 trading statement looks fine, even without numbers !
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 trading statement looks fine, even without numbers !
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
26 Apr 2016 -
Author:
Fabrice Farigoule -
Pages:
2
Lonza released its Q1 16 trading statement, which, as usual, does not include hard numbers. The business development in Q1 is said to be good in both the Speciality Indredients and Pharma & Biotech segments. On this basis, the group expects a double-digit core EBIT growth in H1, while the full-year guidance will be discussed with the H1 results on 20 July. Note, so far, the FY16 guidance (released in January with the FY15 results) points to a growth in sales and a core EBIT growth of at l